KEEGAN JOSEPH D 4
4 · BIO-TECHNE Corp · Filed Oct 30, 2023
Insider Transaction Report
Form 4
BIO-TECHNE CorpTECH
KEEGAN JOSEPH D
Director
Transactions
- Award
Common Stock
2023-10-26+1,625→ 12,309 total - Award
Stock Options (Right to Buy)
2023-10-26+3,937→ 3,937 totalExercise: $61.51Exp: 2033-10-26→ Common Stock (3,937 underlying)
Holdings
- 12,500
Stock Options (Right to Buy)
Exercise: $31.26From: 2018-10-25Exp: 2027-10-26→ Common Stock (12,500 underlying) - 7,592
Stock Options (Right to Buy)
Exercise: $44.96From: 2019-10-24Exp: 2028-10-25→ Common Stock (7,592 underlying) - 6,028
Stock Options (Right to Buy)
Exercise: $63.92From: 2021-10-28Exp: 2030-10-29→ Common Stock (6,028 underlying) - 2,532
Stock Options (Right to Buy)
Exercise: $128.81From: 2022-10-27Exp: 2031-10-28→ Common Stock (2,532 underlying) - 8,044
Stock Options (Right to Buy)
Exercise: $50.41From: 2020-10-24Exp: 2029-10-24→ Common Stock (8,044 underlying) - 3,460
Stock Options (Right to Buy)
Exercise: $73.94From: 2023-10-26Exp: 2032-10-27→ Common Stock (3,460 underlying)
Footnotes (1)
- [F1]This option vests on the earlier of the one year anniversary of the grant date (10/26/2023) or the date of Bio-Techne's 2024 annual meeting of shareholders.